Search for Teva Pharmaceutical Industries Ltd and
    1. May 10, 2016

      Allergan: kicking the habit

      Cold turkey is not always the best way to kick addiction. Sometimes an intermediate step is needed. For Allergan, the...

    2. Fast FT

      May 10, 2016

      Allergan plans $10bn share buyback

      Allergan, the maker of Botox, said it would buy back up to $10bn of its stock, sending shares in the company up by 5...

    Special Reports

    1. Israel: Innovation & Technology

      Israeli tech firms raised a record $4.4bn of venture capital funding last year, even a...
    2. North America Innovative Lawyers

      North America Innovative Lawyers ranks the top law firms, legal teams and individuals ...
    Search more Special Reports on this topic.

    1. March 22, 2016

      Israel’s medical pioneers treat depression with magnets

      In a quiet office on an industrial park in Jerusalem, an Israeli woman in a white coat slowly binds a black coil to the...

    2. January 28, 2016

      Pipeline of big bond sales set to test investor risk appetite

      When the starting gun sounded over 2016’s debt markets, only a handful of corporate borrowers left the blocks. Although...

    3. January 14, 2016

      Why the huge demand for AB InBev’s $46bn bond?

      Chatter at the start of the week caught portfolio managers off guard after a torrid end to 2015: one of the marquee...

    4. December 8, 2015

      Poison pill proves to be a deal-breaker

      A corporate raider, famed for bending the will of shareholders and forcing the hand of executives, secretly acquires...

    5. November 12, 2015

      Mylan/Perrigo: innocents abroad

      Glossy European vacation brochures can all appear the same to uninitiated Americans: castles, churches, cafés on...

    6. September 15, 2015

      Philips to spin off lighting arm and step up medical tech drive

      From the earliest lightbulbs and transistor radios to the first flatscreen televisions, Philips was Europe’s...

    7. September 15, 2015

      Mylan upbeat on prospects for $27bn Perrigo takeover

      Mylan, the generic drugs group, is increasingly confident of pulling off the biggest hostile takeover of the year: the...

    8. August 6, 2015

      Mylan claims US ‘too shareholder-centric’

      Mylan, the generic drugs group, has launched a staunch defence of the tactics it used to repel a $40bn hostile takeover...

    9. August 6, 2015

      Allergan says more acquisitions to come

      Brent Saunders, the frenetic dealmaker who runs Botox-maker Allergan, said there was “certainly more to come” on the...

    10. July 29, 2015

      Wanted: recreational drug users with a nose for business

      Wanted: drug abuser who enjoys snorting opioids. Will pay $250 a day. Thousands of recreational drug users are being...

    11. July 28, 2015

      Pfizer chief executive has ‘sufficient courage’ to pursue deals

      Pfizer is scouting for acquisition targets and has “sufficient courage” to spend its cash on another company, its chief...

    12. July 27, 2015

      Pharma M&A: portfolio theory

      Friendly M&A is cheaper and simpler than the hostile variety. Luckily for Teva Pharmaceutical it had a choice. On...

    13. July 27, 2015

      Weak sales outlook hits machinery makers

      Machinery stocks were under pressure on Monday after analysts at Goldman Sachs issued a downgrade, saying they have not...

    14. July 27, 2015

      Mylan share price plunges after Teva abandons bid

      Shares in drugmaker Mylan plunged almost 14 per cent on Monday after Israeli group Teva Pharmaceutical abandoned its...

    15. July 27, 2015

      Allergan still on the move with $41bn Teva deal

      Having pulled off the biggest takeover of last year, Allergan, the owner of blockbuster wrinkle treatment Botox, is at...

    16. July 26, 2015

      Teva closes in on Allergan’s generics unit

      Teva Pharmaceutical, the Israeli drugmaker, is nearing a deal to acquire Allergan’s generics drug unit for between...

    17. July 6, 2015

      Teva set to lift Mylan bid to up to $43bn

      Teva, the Israeli drugmaker, is preparing to increase its offer for US rival Mylan to as much as $43bn as soon as this...

    18. June 22, 2015

      US appetite for hostile takeovers hits post-crisis high

      Nearly $108bn in potential deals were rejected over the weekend amid a boom in US hostile takeover attempts not seen...

    19. June 1, 2015

      Mylan tells Teva to ‘stop playing games’

      Mylan, a leading generics drugmaker, on Monday demanded that its rival Teva “stop playing games” and either turn its...

    20. May 28, 2015

      Teva pays $1.2bn in US antitrust drugs case

      Teva Pharmaceuticals has agreed to pay $1.2bn over allegations it broke competition law in a record settlement that...

    21. May 12, 2015

      Pharma M&A: Taking stock

      One sign of a top in the merger market is that more deals are done with shares, rather than all in cash. Acquirers —...

    22. May 12, 2015

      Teva bids for Mylan amid pressure on copycat drugmakers

      If timing is everything, then Teva, the world’s biggest maker of generic drugs, has chosen a tricky moment to try to...

    23. April 29, 2015

      Perrigo rebuffs sweetened $35.6bn offer from Mylan

      Mylan, one of the world’s biggest generic drug groups, increased its offer to buy Perrigo to $35.6bn, its latest effort...

    24. April 27, 2015

      Mylan rounds on Teva as it rejects $40bn bid

      Mylan has rejected a $40bn takeover bid from Israel’s Teva, a generic drugs rival double its size, and confirmed its...

    25. April 26, 2015

      No end in sight to wave of pharma dealmaking

      Since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions — greater than...

    26. April 24, 2015

      Three-way merger battle in drugs industry hots up

      Perrigo rejected a formal takeover offer from its bigger generic drugs rival Mylan, escalating a three-way takeover...

    27. April 23, 2015

      Mylan readies its poison pill defences

      Israel’s Teva faces an uphill battle in its $40bn takeover pursuit of rival generics drugmaker Mylan, thanks to recent...

    28. April 21, 2015

      Teva seeks cushion against loss of patent protection

      Teva Pharmaceuticals’ $40bn takeover offer for Mylan thrusts into the spotlight a company that has long been a pillar...

    29. April 21, 2015

      Teva/Mylan: brand management

      Could a branded drug be the impetus for dealmaking among generics manufacturers? On Tuesday, Israeli Teva...

    30. April 21, 2015

      Harley-Davidson brakes on lower shipment forecasts

      Harley-Davidson shares were on of the biggest decliners on the S&P 500, after the company lowered its 2015 motorcycle...

    31. April 21, 2015

      Israel’s Teva offers $40.1bn for US drugmaker Mylan

      Teva, the largest generic drugmaker in the world, set the stage for the biggest pharma deal of 2015 by launching an...

    32. April 17, 2015

      Mylan dismisses takeover interest from Teva Pharmaceuticals

      Israel’s Teva Pharmaceuticals is considering a bid to acquire rival generic drugmaker Mylan even as the $33bn US...

    33. March 30, 2015

      UnitedHealth pays $13bn for drug-benefits manager amid deal flurry

      The largest US health insurer is to spend almost $13bn to buy a company that manages prescription medicines for 35m...

    34. October 3, 2014

      Mylan surges after guidance lift

      Mylan climbed after the Pennsylvania-based pharmaceutical company lifted its third-quarter guidance on recent product...

    35. August 3, 2014

      Private equity eyes drug brands purchase

      Private equity groups are exploring a $10bn plan to buy hundreds of older drug brands from GlaxoSmithKline and Sanofi...

    36. July 14, 2014

      Teva faces fresh shareholder showdown over management structure

      Teva is facing a fresh confrontation with shareholders after an activist investor accused the drugmaker of reneging on...

    37. July 9, 2014

      European regulators fine Servier of France

      European regulators have fined Servier of France and several other drugmakers €428m for blocking the introduction of...

    38. June 15, 2014

      Women in Business – Shira Kaplan, MBA student

      Shira Kaplan is an MBA student currently studying on the part-time programme at the University of St Gallen in...

    Search for Teva Pharmaceutical Industries Ltd and